Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

F. Hoffmann-la Roche Ag

Memory Pharmaceuticals Corporation

Joan Marie Caroon

Francisco Javier Lopez-Tapia

Shu-Hai Zhao

Robin D Clark

Ashok Tehim

Jacob Berger

Xiaoming Zhang

Cyrus K Becker

Christine E Brotherton-Pleiss

Michael Patrick Dillon

Joseph M Muchowski

Francisco Xavier Talamas

Richard A Schumacher

Sharada Shenvi Labadie

Keith Adrian Murray Walker

Dov Nitzan

Jürg Roland Pfister

Chris Richard Melville

Fernando Padilla

Ralph New Harris, Iii

David Bruce Repke

Lawrence Emerson Fisher

Hans Maag

Allen T Hopper

Robert F Dunn

Clara Jeou Jen Lin

Nancy Elisabeth Krauss

Roberto P Rosenkranz

Lee Edwin Lowrie, Jr

Deborah L McClelland

Thomas E Renau

Sharathchandra Surendra Hegde

Jr Lee Edwin Lowrie

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Dihydropyrimidone amides as P2X7 modulators

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

[object Object]

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Compounds of the formula I: wherein m, n, p, X, Ar, R, R, R, Rand Rare as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.

This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: 

Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists

This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I:wherein Z is &#x2014;C(O)&#x2014; or &#x2014;S(O)&#x2014;, X is carbon or nitrogen, Y is carbon, and X&#x2014;Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

This invention relates to muscarinic receptor antagonist compounds selected from the group of compounds represented by Formula I:

2-arylethyl-(piperidin-4-ylmethyl)amine derivatives

Dopamine agonist compounds disclosed are useful in treating hypertension and congestive heart failure in mammals. The compounds have the following general formula (I) ##STR1## wherein: X is nitrogen or CH;

Benzylpyrrolidine derivatives as dopamine agonists

Growing community of inventors

Mountain View, CA, United States of America

Joan Marie Caroon